Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian markets fall nearly 2%
Mon, 9 Mar 03:30 pm

Indian markets fell about 2% as investors' concern grew amidst speculation that US might increase its interest rates earlier than expected. Losses of BSE-Sensex and NSE-Nifty deepened to 1.8% each. While BSE Sensex has lost over 500 points, NSE Nifty has lost over 160 points. Banks, Capital Goods and Information Technology were today's biggest losers. S&P BSE Midcap and S&P BSE Smallcap have lost over 1% and 0.8% each, though lesser than broader indices.

Crude oil price has fallen marginally by Rs 3 and is currently trading at Rs 3,135 per barrel. Gold prices per 10 grams have increased 0.33% or Rs 100 to Rs 26,100, while the Silver prices have increased 0.43% or Rs 157 to Rs 36,129 per kilogram. The value of Indian Rupee has gained 0.6% and is trading at Rs 62.55 against the U.S. Dollar.

European markets remained cautious over the fate of end of the Greece crisis as the finance ministers of the Eurozone meet today at Brussels to evaluate and discuss the proposed economic reforms put forward by Greece's lawmakers. DAX and FTSE are trading in the red with 0.3% and 0.5% losses, respectively.

Pharmaceutical stocks have buoyed the losses for most part of today's trading session. Apart from companies like Natco Pharma and Lupin, Suven Life Sciences has also gained over 1% as it received one patent each from Eurasia and Israel for medicines that are used to treat diseases like Alzheimer's disease, Parkinson's disease and Schizophrenia. The validity of these patents will expire in 2029 and 2030, respectively.

Container Corporation gained more than 8% as the Reserve Bank of India permitted the Foreign Institutional Investors (FIIs) to invest up to 34% of the paid up capital of the company. The company's primary operations include transport related service business. The RBI also said that the limit of foreign holding has gone below the approved limit, hence, any restrictions that were placed on purchase of shares were withdrawn with immediate effect.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets fall nearly 2%". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.